Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Glioblastoma Multiforme Market?
Recent years have seen significant growth in the glioblastoma multiforme market size. Predictions indicate an increase from $2.50 billion in 2024 to $2.71 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. Factors such as the rising incidence of glioblastoma multiforme, an expanding healthcare infrastructure, enhanced awareness, increased access to cutting-edge treatments, and a growing aging population have contributed to the growth observed in the historical period.
What Growth Rate Is Forecasted for the Glioblastoma Multiforme Market by 2029?
The market size for glioblastoma multiforme is poised to experience robust expansion in the next several years. Its value is predicted to reach $3.69 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this projected growth include a rise in occurrences of brain and other nervous system cancers, broader acceptance of surgical procedures, amplified awareness, prompt diagnosis of the disease, and an expansion in research and development endeavors. In the forecast period, influential trends include progress in medical technology, forward movement in imaging techniques, tailored medicine, the use of AI in diagnosis, as well as ongoing technological and scientific breakthroughs.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp
Which Key Companies Are Shaping the Future of the Glioblastoma Multiforme Market?
Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.
Which Factors Are Driving Demand in the Glioblastoma Multiforme Industry?
The increasing instances of brain disorders are anticipated to fuel the growth of the glioblastoma multiforme market. Brain disorders are conditions that impair the structure or function of the brain, leading to emotional, cognitive, or physical deficiencies. The escalation in brain disorder cases can be attributed to factors such as advanced age, prolonged life span, lifestyle choices, and enhanced diagnostic capabilities. Comprehension of brain disorders aids in progressing research on glioblastoma multiforme (GBM), contributing to improved early detection, breakthrough treatments, and better patient results. By exploring neurological disorders, researchers can discover genetic and molecular associations that play a role in the development of GBM. For example, as per Dementia Australia, a non-profit organization based in Australia, about 433,300 Australians were reported to be living with dementia in February 2025, with a projected increase to 812,500 by 2054. Moreover, younger-onset dementia is estimated to affect approximately 29,000 people in 2025 and increase to 41,000 by 2054. Consequently, the upsurge in brain disorder cases will propel the expansion of the glioblastoma multiforme market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp
How Is the Glioblastoma Multiforme Market Segmented by Several Divisions?
The glioblastoma multiforme market covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy
What are the Emerging Market Trends Driving the Growth of the Glioblastoma Multiforme Industry?
Leading firms in the glioblastoma multiforme market are channeling their efforts into creating advanced treatment methods, such as CAR T-cell therapies, to cater to the unfulfilled medical needs surrounding this aggressive form of cancer. CAR T-cell therapies serve as a type of immunotherapy, which involves the alteration of a patient’s T-cells to fight cancer cells more effectively. For example, Chimeric Therapeutics Limited, a biotech firm based in Australia, embarked on a Phase IB clinical study for CHM 1101 (CLXT CAR T) therapy in June 2023, aimed at treating recurrent or progressive glioblastoma multiforme (GBM). The multi-center trial targets to assess the safety and efficiency of this therapy along with determining the commended dose for Phase 2. The initial Phase 1a outcomes showed disease stability that will serve as a foundation for more development. The gathered data will be utilized by the company for designing a registration trial and soliciting regulatory feedback.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report
Which Regions Are Driving Growth in the Glioblastoma Multiforme Market?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21191
This Report Delivers Insight On:
1. How big is the glioblastoma multiforme market, and how is it changing globally?
2. Who are the major companies in the glioblastoma multiforme market, and how are they performing?
3. What are the key opportunities and risks in the glioblastoma multiforme market right now?
4. Which products or customer segments are growing the most in the glioblastoma multiforme market?
5. What factors are helping or slowing down the growth of the glioblastoma multiforme market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model